Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 53.05
+3.75 (7.61%)
May 7, 2026, 4:08 PM HKT
HKG:2315 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 290.48 | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 |
Depreciation & Amortization | 132.65 | 132.65 | 135.24 | 179.3 | 174.1 | 128.1 |
Other Amortization | 27.81 | 27.81 | 33.93 | 3.15 | - | - |
Loss (Gain) From Sale of Assets | -1 | -1 | 0 | -1.83 | 0.08 | -0.39 |
Asset Writedown & Restructuring Costs | 0.22 | 0.22 | -0.01 | - | - | - |
Loss (Gain) From Sale of Investments | 20.1 | 20.1 | 30.11 | -0.15 | -44.7 | -2.13 |
Loss (Gain) on Equity Investments | - | - | - | 10.03 | 14.77 | 0.4 |
Stock-Based Compensation | 35.24 | 35.24 | 22.64 | 30.98 | 15.31 | 27.75 |
Provision & Write-off of Bad Debts | 11.51 | 11.51 | 9.45 | 4.28 | 1.42 | 3.12 |
Other Operating Activities | 16.78 | 23.21 | 83.55 | 89.8 | 42.04 | 33.13 |
Change in Accounts Receivable | -59.69 | -59.69 | -103.69 | -39.02 | -4.59 | -35.86 |
Change in Inventory | -15.6 | -15.6 | -17.19 | 3.79 | -6.4 | -29.96 |
Change in Accounts Payable | 25.74 | 25.74 | -14.65 | 11.9 | 47.35 | 19.04 |
Change in Unearned Revenue | - | - | - | 9.98 | -8.07 | 16.75 |
Change in Income Taxes | - | - | - | - | -0.8 | - |
Change in Other Net Operating Assets | -3.08 | -3.08 | 1.17 | 4.1 | 68.17 | 19.86 |
Operating Cash Flow | 481.11 | 370.25 | 211.25 | -76.65 | -303.27 | -365.78 |
Operating Cash Flow Growth | 61.36% | 75.27% | - | - | - | - |
Capital Expenditures | -182.6 | -87.82 | -37.13 | -126.62 | -240.27 | -198.67 |
Sale of Property, Plant & Equipment | 0.3 | 0.29 | 1.11 | 26.34 | 1.64 | 4.76 |
Divestitures | - | - | - | - | -6.86 | - |
Investment in Securities | -403.25 | -98.12 | -101.09 | - | 91.76 | 109.78 |
Other Investing Activities | -98.59 | 0.79 | - | - | - | - |
Investing Cash Flow | -684.14 | -184.86 | -137.12 | -100.28 | -153.74 | -84.13 |
Long-Term Debt Issued | - | 248.27 | 235.67 | 319.91 | 209.6 | - |
Short-Term Debt Repaid | - | - | -2 | - | - | - |
Long-Term Debt Repaid | - | -386.76 | -303.81 | -172.98 | -68.77 | -57.13 |
Total Debt Repaid | -519.98 | -386.76 | -305.81 | -172.98 | -68.77 | -57.13 |
Net Debt Issued (Repaid) | -165.05 | -138.49 | -70.15 | 146.93 | 140.83 | -57.13 |
Issuance of Common Stock | 1,169 | 1,169 | - | - | 521.06 | 311.04 |
Repurchase of Common Stock | -18.07 | -18.07 | -9.51 | -8.2 | -18.99 | - |
Common Dividends Paid | -14.75 | -15.05 | -15.19 | - | - | - |
Other Financing Activities | -291.3 | -17.32 | 2.82 | -176.55 | -55.69 | -34.47 |
Financing Cash Flow | 679.63 | 979.86 | -92.03 | -37.82 | 587.2 | 219.44 |
Foreign Exchange Rate Adjustments | -4.64 | 2.84 | 2.75 | 3.47 | 14.24 | -0.38 |
Net Cash Flow | 471.97 | 1,168 | -15.15 | -211.28 | 144.44 | -230.85 |
Free Cash Flow | 298.51 | 282.43 | 174.12 | -203.26 | -543.54 | -564.45 |
Free Cash Flow Growth | 16.43% | 62.21% | - | - | - | - |
Free Cash Flow Margin | 19.10% | 20.48% | 17.76% | -28.35% | -101.81% | -159.20% |
Free Cash Flow Per Share | 0.74 | 0.70 | 0.41 | -0.51 | -1.43 | -1.56 |
Cash Interest Paid | - | - | - | 24.08 | 17 | 7.66 |
Cash Income Tax Paid | 47.73 | 49.07 | 34.05 | 0.64 | - | - |
Levered Free Cash Flow | 6.4 | 434.9 | -0.26 | -231.5 | -423.55 | -397.16 |
Unlevered Free Cash Flow | 50.77 | 479.28 | 57.04 | -169.1 | -388.46 | -372.52 |
Change in Working Capital | -52.68 | -52.68 | -137.22 | -9.24 | 95.65 | -10.18 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.